Global Anti-epileptic Drugs for Pediatrics Market is expected to reach US$ 1506.56 Mn by 2026 from US$ 920 Mn in 2019, at a CAGR of 7.3% during forecast period.Global Anti-epileptic Drugs for Pediatrics Market Overview:
Epilepsy is a brain condition that causes recurrent seizures in people. Antiepileptic drugs are used to prevent seizures rather than treat epilepsy. They are normally administered for children who have frequent seizures, preferably after a particular epilepsy condition has been diagnosed and the likelihood of future seizures has been determined.Global Anti-epileptic Drugs for Pediatrics Market Dynamics:
Rising prevalence of epilepsy and other neural disorders are the major factors driving the growth of market. The World Health Organization (WHO) states that epilepsy affects approximately 50 million people worldwide, making it one of the most common neurological disorders. The disorder is found to be more common in children than in adults, leading to a higher likelihood for general practitioners to consult patients with epilepsy on a regular basis. The increasing prevalence of other neurological disorders such as anxiety and bipolar disorders are among the main demand drivers for anti-epilepsy drugs. Additionally, initiatives undertaken by the government to coordinate various epilepsy awareness programs as well as to make treatment facilities available are expected to accelerate market growth during the forecast period. Furthermore, ongoing R&D activities in pharmaceuticals are expected to fuel market growth by developing new drug therapies. There are large numbers of drug candidates in production. Also, the rising geriatric population and dietary preferences are two important factors driving the global antiepileptic drugs market growth. There are currently over 26 Anti-epileptic Drugs (AEDs) available in the market to treat different epileptic syndromes. AED can fully suppress seizures in about 70% of cases of pediatric epilepsy. In addition, attempts to build AEDs with novel mechanisms of action are expected to change care patterns. Biscayne Pharmaceuticals Inc., a clinical-stage biotechnology company headquartered in the United States, is focused on using its lead compound BIS-001, which has a novel mechanism of action, to treat refractory types of focal epilepsy. However, the global pediatric epilepsy therapeutics market is expected to be hampered by certain factors such as a lack of knowledge about diseases in developing countries, dearth of medical facilities in low and middle-income countries, as well as a reluctance to implement epilepsy medications. Along with this, the absence of a proper supply chain for epilepsy medications, and the side effects associated with treatment, are expected to limit the market growth. The report has profiled seventeen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.Global Anti-epileptic Drugs for Pediatrics Market Segment Analysis:
The Global Anti-epileptic Drugs for Pediatrics Market is segmented on the basis of Drug Type and Distribution Channel. Based on Drug Type, 3rd generation drugs segment accounted for the largest market share XX % in 2019. The segment is projected to register a CAGR of 4.1% during the forecast period. Third-generation medications such as UCB's Keppra (levetiracetam) and GlaxoSmithKline's (GSK's) Lamictal (lamotrigine) have quickly gained popularity as first-line therapies. These new antiepileptic medications are undergoing extensive clinical trials to determine their effectiveness and utility in the treatment of refractory epilepsy patients. Increasing adoption of these drugs is expected to aid the segment growth.To know about the Research Methodology :- Request Free Sample Report
Global Anti-epileptic Drugs for Pediatrics Market Regional Insights:
North America dominated the global market in 2019. North America is expected to continue its dominance throughout the forecast period. The presence of favorable government policies, robust research and development programs, and the introduction of new generation anti-epileptic drugs are expected to propel market growth. Along with this, the rising disease diagnosis rates of neurological disorders are expected to keep this area in the lead over the forecast period. In addition, an increase in the number of awareness campaigns about the availability of unique drugs and treatment options, will contribute to the development. The report also helps in understanding Global Anti-epileptic Drugs for Pediatrics Market dynamics, structure by analyzing the market segments and project the Global Anti-epileptic Drugs for Pediatrics Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-epileptic Drugs for Pediatrics Market make the report investor’s guide.Global Anti-epileptic Drugs for Pediatrics Market, Key Developments:
In September 2019, GW Pharmaceuticals plc. a biopharmaceutical corporation based in the United Kingdom, announced that EPIDYOLEX, a groundbreaking treatment for Dravet syndrome or Lennox-Gastaut syndrome (LGS), has obtained European Commission (EC) approval as adjunctive therapy for seizures. It is intended for patients who are at least 2 years old. It will be released in the European Union.Global Anti-epileptic Drugs for Pediatrics Market Scope: Inquire before buying
Global Anti-epileptic Drugs for Pediatrics Market Report Coverage Details Base Year: 2019 Forecast Period: 2020-2026 Historical Data: 2016 to 2019 Market Size in 2019: US $ 920 Bn. Forecast Period 2020 to 2016 CAGR: 7.3% Market Size in 2026: US $ 1506.56 Bn. Segments Covered: by Drug Type • 1st Generation • 2nd Generation • 3rd Generation by Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Global Anti-epileptic Drugs for Pediatrics Market, By Region:
• North America • Europe • South America • MEA • APACGlobal Anti-epileptic Drugs for Pediatrics Market, Key players:
• Mylan N.V. • Cephalon, Inc. • GlaxoSmithKline plc • Janssen Pharmaceuticals • Novartis AG • Pfizer, Inc. • Sanofi S.A. • UCB Pharma Limited • Sunovion Pharmaceuticals Limited • Valeant Pharmaceuticals International, Inc. • Zynerba • Zogenix • Insys Therapeutics • Bausch Health Companies Inc. • Johnson & Johnson Service • Teva Pharmaceutical Industries Ltd. • Sumitomo Dainippon Pharma Co., Ltd.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Anti-epileptic Drugs for Pediatrics Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Anti-epileptic Drugs for Pediatrics Market 3.4. Geographical Snapshot of the Anti-epileptic Drugs for Pediatrics Market, By Manufacturer share 4. Global Anti-epileptic Drugs for Pediatrics Market Overview, 2019-2026 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Anti-epileptic Drugs for Pediatrics Market 5. Supply Side and Demand Side Indicators 6. Global Anti-epileptic Drugs for Pediatrics Market Analysis and Forecast, 2019-2026 6.1. Global Anti-epileptic Drugs for Pediatrics Market Size & Y-o-Y Growth Analysis. 7. Global Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 7.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 7.1.1. 1st Generation 7.1.2. 2nd Generation 7.1.3. 3rd Generation 7.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 7.2.1. Hospital Pharmacies 7.2.2. Retail Pharmacies 7.2.3. Online Pharmacies 8. Global Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2019-2026 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 9.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 9.1.1. 1st Generation 9.1.2. 2nd Generation 9.1.3. 3rd Generation 9.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 9.2.1. Hospital Pharmacies 9.2.2. Retail Pharmacies 9.2.3. Online Pharmacies 10. North America Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 11.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 11.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 12. Canada Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 12.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 12.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 13. Mexico Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 13.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 13.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 14. Europe Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 14.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 14.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 15. Europe Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 16.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 16.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 17. France Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 17.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 17.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 18. Germany Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 18.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 18.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 19. Italy Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 19.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 19.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 20. Spain Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 20.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 20.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 21. Sweden Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 21.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 21.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 22. CIS Countries Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 22.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 22.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 23. Rest of Europe Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 23.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 23.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 24. Asia Pacific Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 24.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 24.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 25. Asia Pacific Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 26.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 26.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 27. India Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 27.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 27.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 28. Japan Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 28.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 28.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 29. South Korea Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 29.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 29.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 30. Australia Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 30.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 30.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 31. ASEAN Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 31.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 31.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 32. Rest of Asia Pacific Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 32.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 32.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 33. Middle East Africa Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 33.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 33.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 34. Middle East Africa Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 35.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 35.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 36. GCC Countries Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 36.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 36.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 37. Egypt Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 37.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 37.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 38. Nigeria Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 38.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 38.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 39. Rest of ME&A Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 39.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 39.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 40. South America Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 40.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 40.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 41. South America Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 42.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 42.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 43. Argentina Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 43.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 43.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 44. Rest of South America Anti-epileptic Drugs for Pediatrics Market Analysis and Forecasts, 2019-2026 44.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 44.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Anti-epileptic Drugs for Pediatrics Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Mylan N.V. 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Cephalon, Inc. 45.3.3. GlaxoSmithKline plc 45.3.4. Janssen Pharmaceuticals 45.3.5. Novartis AG 45.3.6. Pfizer, Inc. 45.3.7. Sanofi S.A. 45.3.8. UCB Pharma Limited 45.3.9. Sunovion Pharmaceuticals Limited 45.3.10. Valeant Pharmaceuticals International, Inc. 45.3.11. Zynerba 45.3.12. Zogenix 45.3.13. Insys Therapeutics 45.3.14. Bausch Health Companies Inc. 45.3.15. Johnson & Johnson Service 45.3.16. Teva Pharmaceutical Industries Ltd. 45.3.17. Sumitomo Dainippon Pharma Co., Ltd. 46. Primary Key Insights